Testosterone enanthate

Testosterone enanthate is a long-acting esterified form of testosterone that is pharmacologically closely related to testosterone cypionate. Esterification with enanthate (heptanoate) at the 17-beta hydroxyl position increases lipid solubility and creates a sustained-release depot following intramuscular injection. The enanthate ester produces a slightly shorter duration of action than cypionate — peak plasma testosterone levels within 24–48 hours after injection, with an effective duration of action of approximately 7–10 days — though the clinical difference between the two esters at equivalent doses and injection frequencies is generally considered small. The choice between testosterone cypionate and enanthate in clinical practice often comes down to prescriber preference, regional availability, and individual patient response.¹

Like testosterone cypionate, testosterone enanthate is a Schedule III controlled substance under the Controlled Substances Act.

Testosterone enanthate injection is indicated for replacement therapy in conditions associated with deficiency or absence of endogenous testosterone:¹

• Primary hypogonadism (congenital or acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
• Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.

As with testosterone cypionate, the FDA label does not establish safety and efficacy for "age-related hypogonadism" (late-onset hypogonadism), and use in men with age-related testosterone decline without structural or genetic hypogonadism is off-label.¹

Testosterone enanthate has also been used off-label as part of gender-affirming hormone therapy for transgender men and non-binary individuals.

The FDA label documents a dosing range of 50 to 400 mg intramuscularly every 2 to 4 weeks for replacement in hypogonadal males.¹ As with testosterone cypionate, clinical practice widely uses smaller, more frequent injections — commonly 100–200 mg weekly, or smaller doses administered multiple times per week — to achieve more stable serum testosterone levels and reduce symptomatic fluctuations. Dosing is individualized based on clinical response and laboratory monitoring of serum testosterone, hematocrit, and lipid parameters.

Real-world practice: Identical split-dosing rationale as testosterone cypionate. The slightly shorter ester half-life makes split dosing (twice weekly or every 3.5 days) even more beneficial for level stability. Volume calculations depend on vial concentration — verify with your prescribing physician or pharmacist.

Intramuscular injection (labeled route).

Store at controlled room temperature. Protect from light. As with other oil-based testosterone preparations, crystallization may occur at low temperatures; warming and gently rolling the vial resolves this. Single-dose and multi-dose vials are available.¹

The safety and pharmacological profile of testosterone enanthate is substantially identical to testosterone cypionate at equivalent doses and injection frequencies. All of the considerations described for testosterone cypionate apply equally here — erythrocytosis, cardiovascular monitoring, suppression of spermatogenesis and fertility impact, prostate effects, lipid effects, and misuse potential.¹

One clinical note specific to enanthate formulations: Some physicians and patients report subjective differences in how they feel on cypionate versus enanthate, often attributed to the slight difference in ester half-life and release kinetics. These differences are pharmacologically real but modest; individual response varies and is not reliably predictable.

Testosterone enanthate is also the testosterone ester used in some combination products (for example, Aveed, which uses testosterone undecanoate — a different ester — and Xyosted, a subcutaneous enanthate formulation approved specifically for once-weekly subcutaneous injection). Xyosted's label includes additional data from the TRAVERSE study on cardiovascular outcomes and is the labeled subcutaneous enanthate product; the standard generic testosterone enanthate injection is labeled for intramuscular use only.¹